← All trials
NCT04808752
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2021
- Primary completion
- Mar 15, 2023
- Completion date
- Jul 15, 2023
- First posted
- Mar 22, 2021
- Last posted
- Apr 2, 2021
- Enrollment
- 60
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Chinese Academy of Medical SciencesLead sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.Collaborator
- Zhejiang UniversityOverall official - principal investigator
- Central South UniversityOverall official - principal investigator
- Fujian Medical UniversityOverall official - principal investigator
- Heilongjiang Cancer Hospital，Heilongjiang，ChinaOverall official - principal investigator
- Henan Medical UniversityOverall official - principal investigator
- Huzhou UniversityOverall official - principal investigator
- Ningbo Yinzhou People's HospitalOverall official - principal investigator
- Meizhou City Hospital Of Guangdong ProvienceOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
- Zhengzhou UniversityOverall official - principal investigator
- Wenzhou Medical UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.